



COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

1648

APR 24 2002

PATENT

TECH CENTER 1600/2900

LOCKET NO: 17171CIP4DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Klein et al.
Serial No: 09/685,828
Conf. No: 4591
Filed: October 10, 2000

For: METHODS OF IDENTIFYING
COMPOUNDS HAVING
NUCLEAR RECEPTOR NEGATIVE
HORMONE AND/OR ANTAGONIST
ACTIVITIES

Examiner: Myron G. Hill

Group Art Unit: 1648

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail and addressed to: Box Restriction Requirement-Non Fee, Assistant Commissioner for Patents, Washington, D.C. 20231 on:

Date of Deposit:

4/9/2002

Person making Deposit:

BONNIE FERGUSON

Signature:

Bonnie Ferguson

Date of Signature:

4/9/2002

REPLY TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

This Reply to Restriction Requirement is being filed in reply to the Restriction Requirement mailed March 26, 2002. Applicants reply as follows:

REMARKS

Applicants elect to prosecute claims 21-41, and therefore cancel claims 42 and 43 without prejudice. Additionally, Applicants elect the species of the claimed method wherein the receptor is a retinoid receptor. This species is readable on claims 21, 22, 23, 24, 25, 33, 35 and 39.

Applicants note that under MPEP 809.02(c)(B)(1) at such time as a generic claim is found to be patentable, the claims drawn to non-elected species will be examined.

If there is any fee due in connection with this Communication, please use Deposit Account 01-0885.

Respectfully submitted,

Dated:

4/8/02

By:

Carlos A. Fisher

Registration No. 36,510
Attorney of Record

Allergan, Inc.
Carlos Fisher-T2-7H
2525 Dupont Drive
Irvine, CA 92612
Telephone: 714-246-4920
Fax: 714-246-4249